



## Nanox Announces Multi-Segment Healthcare Collaboration with Monarch Medical Management to Expand Access to Advanced Medical Imaging

September 18, 2025

*Collaboration spans workers' compensation, nursing homes, and outpatient clinics*

PETACH TIKVA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- [NANO-X IMAGING LTD](#) ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration between its U.S. subsidiary Nanox Impact Inc. and Monarch Medical Management and Billing LLC ("Monarch"), an experienced healthcare management organization with established relationships across industry sectors, to deploy Nanox's advanced imaging solutions across multiple healthcare segments including workers' compensation, nursing home facilities, and outpatient clinics.

As part of the collaboration, Nanox will establish a comprehensive imaging network by deploying its technology across Monarch's associated healthcare facilities, including nursing homes, outpatient clinics, and dedicated imaging centers for workers' compensation cases. Monarch has identified over a dozen initial sites that will undergo a proof-of-concept phase, after which Nanox intends to expand the network nationwide.

The collaboration will provide patients across multiple care settings with access to advanced imaging services. Workers' compensation claimants, nursing home residents, outpatient clinic patients and others within Monarch's network will have access to Nanox's end-to-end medical imaging solutions. These include the [Nanox.ARC](#), an advanced 3D digital tomosynthesis imaging system; [Nanox's suite of AI-powered software](#), that analyzes routine CT scans to identify early signs of chronic conditions; and teleradiology services.

"This collaboration addresses critical imaging access challenges across multiple healthcare segments by providing faster access to high-quality imaging services that can accelerate accurate diagnosis and treatment decisions for patients," said Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox. "We look forward to working with Monarch as they provide management and consulting services to support our growing imaging network, representing another step in the U.S. expansion of the Nanox.ARC system."

Nydia Soriano, CEO of Monarch, said, "The integration of Nanox's advanced imaging technology is an exciting expansion of the comprehensive healthcare solutions that Monarch Medical Management has provided for more than 30 years. Nanox's focus on early disease detection and preventive care aligns perfectly with our mission to deliver comprehensive care across our multi-segment healthcare settings. This collaboration will enhance patient outcomes across the diverse populations we serve."

### About Nanox

Nanox (NASDAQ: NNOX) is focused on driving the world's transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.

Nanox's vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI to enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source digital tomosynthesis system that is cost-effective and user-friendly; Nanox.AI LTD – an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages and stores data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox's subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit [www.nanox.vision](http://www.nanox.vision)

### Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company's research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as "can," "might," "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "should," "could," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox's ability to complete development of the Nanox System; (ii) Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox's ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox's ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox's expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox's ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and

regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox's actual results to differ from those contained in the Forward-Looking Statements, see the section titled "Risk Factors" in Nanox's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company's expectations.

## **Contacts**

### **Media Contact:**

Ben Shannon

ICR Healthcare

[NanoxPR@icrinc.com](mailto:NanoxPR@icrinc.com)

### **Investor Contact:**

Mike Cavanaugh

ICR Healthcare

[mike.cavanaugh@icrhealthcare.com](mailto:mike.cavanaugh@icrhealthcare.com)